BEST Subsidiary RI Research Instruments Awarded $7.4 Million Contract for 40 Accelerating Structures for Swedish MAX IV Synch...
November 16 2010 - 7:00AM
Business Wire
RI Research Instruments GmbH, a majority-owned subsidiary of
Bruker Energy & Supercon Technologies, Inc. (BEST), today
announced the award of an approximately 5.5 million Euro (USD $7.4
million) contract from Lund University’s MAX-lab for the supply of
40 radio-frequency (rf) structures and related bunch compressing
cavities for the linear accelerator (linac) of the MAX IV
project.
MAX IV is intended to be the next generation synchrotron
radiation facility in Sweden. The main sources at MAX IV are two
storage rings (1.5 GeV and 3 GeV) with state-of-the-art production
of soft and hard x-rays. The linac injector will also provide
pulses to a short pulse facility. This solution allows the
production of synchrotron radiation with optimal characteristics in
a wide energy region, fulfilling the needs of many diverse research
areas.
This contract covers the manufacturing and high rf power
conditioning of 40 normal-conducting rf structures, together with
20 bunch compressing (SLED) cavities, together comprising the
complete injection linac. The design is based on the 3 GHz
accelerating structure design used for RI’s injection linacs
previously supplied to major research laboratories in Switzerland,
Great Britain, Australia, Germany, and in production for Taiwan,
the Netherlands, and Brookhaven’s NSLS II in the United States.
Delivery is expected between 2012 and 2013.
Dr. Michael Peiniger, Managing Director of RI Research
Instruments, explained: “Manufacturing of normal conducting
accelerating structures is complementary to our superconducting
cavity business, and this award represents a milestone in further
securing our base business.”
Hanspeter Vogel, Director of RI Research Instruments, added:
“These accelerating structures will be delivered with high power
conditioning ready for operation, strengthening our market position
in terms of delivery of turnkey systems.”
About MAX-lab: MAX-lab is a national laboratory operated
jointly by the Swedish Research Council and Lund University. MAX IV
will be the next generation synchrotron radiation facility in
Sweden. For more information: www.maxlab.lu.se
About RI Research Instruments and Bruker Energy &
Supercon Technologies, Inc.:
RI Research Instruments GmbH is a world leader in the
development and manufacturing of normal and superconducting rf
cavities and systems, linear accelerators, as well as special
products for physics and energy research, scientific, medical and
industrial applications. RI products also include high-performance
electron and ion sources, particle beamlines and diagnostics,
research reactor subunits as well as vacuum and cryogenic systems.
BEST has operations in the US, the UK and Germany, and is a
wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).
For more information, please visit: www.research-instruments.de or www.bruker-est.com
CAUTIONARY STATEMENT OF BEST
This press release contains forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy and
plans and objectives of management for future operations, are
forward-looking statements. In many cases, you can identify
forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential,” “continue” or other similar words.
These forward-looking statements are predictions, not
guarantees. These statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, levels of activity, performance or achievements to
materially differ from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. Risks and uncertainties that could
cause actual results to differ materially from those projected,
include, but are not limited to, the integration of businesses we
have acquired or may acquire in the future, changing technologies,
product development, the cost and pricing of our products,
manufacturing, competition, dependence on collaborative partners
and key suppliers, capital spending and government funding
policies, changes in governmental regulations, intellectual
property rights, litigation, and exposure to foreign currency
fluctuations. Because forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be
predicted or quantified, you should not rely on these
forward-looking statements as guarantees of future events.
The forward-looking statements in this press release represent
our views as of the date of this press release. We anticipate that
subsequent events and developments may cause our views to change.
However, while we may elect to update these forward-looking
statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable
law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to
the date of this press release.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Sep 2023 to Sep 2024